Morgan Stanley Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $45

Moomoo News08:32 ET · Ratings

A Quick Look at Today's Ratings for Rocket Pharmaceuticals(RCKT.US), With a Forecast Between $45 to $55

Moomoo News08:00 ET · Ratings

Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference

Businesswire07:00 ET

Rocket Pharmaceuticals Price Target Maintained With a $52.00/Share by Needham

Dow Jones05:34 ET · Ratings

Analysts' Opinions Are Mixed on These Healthcare Stocks: Sight Sciences (SGHT) and Rocket Pharmaceuticals (RCKT)

TipRanks05:30 ET · Ratings

Positive Outlook for Rocket Pharmaceuticals Amidst Significant Trial Progress and Regulatory Engagement

TipRanks00:46 ET